Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Pliant Therapeutics (DE:9PT)
BERLIN:9PT
RESEARCH TOOLSreports
Pliant Therapeutics (9PT) Stock Price & Analysis
1 Followers
9PT Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€10.70 - €25.80
Previous Close€11
Volume0.00
Average Volume (3M)N/A
Market Cap
€665.60M
Enterprise Value€212.64M
Total Cash (Recent Filing)$494.25M
Total Debt (Recent Filing)$11.37M
Price to Earnings (P/E)N/A
Beta-0.39
Next Earnings
May 06, 2024EPS Estimate
-€0.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/Revenue134.58
Enterprise Value/Gross Profit134.58
Enterprise Value/Ebitda-1.59
Forecast
1Y Price Target
€40.00Price Target Upside257.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
Pliant Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical Development ProgressThe ongoing Phase 2b BEACON-IPF trial for bexotegrast shows promise, and its success could potentially meet FDA criteria for pivotal trial registration.
Financial StabilityThe company has upsized its loan facility from $100M to $150M, providing a stronger financial position for continued development.
Regulatory MilestonesPLRX has received FDA Fast-Track designation and EMA Orphan Drug designation for bexotegrast, indicating regulatory confidence in the treatment's potential.
Bears Say
Clinical Trial ResultsThe top dose of the drug showed worse efficacy across key endpoints, complicating the dose-response interpretation and narrowing perceived treatment effect.
Drug EfficacyBexotegrast did not reach statistical significance in the key exploratory efficacy endpoint of ELF score.
Financial PerformancePLRX reported a net loss driven by increased operational expenses, despite a decrease in stock-based compensation.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
0.73% Other Institutional Investors
99.27% Public Companies and
Individual Investors
9PT FAQ
What was Pliant Therapeutics’s price range in the past 12 months?
Pliant Therapeutics lowest stock price was €10.70 and its highest was €25.80 in the past 12 months.
What is Pliant Therapeutics’s market cap?
Currently, no data Available
When is Pliant Therapeutics’s upcoming earnings report date?
Pliant Therapeutics’s upcoming earnings report date is May 06, 2024 which is in 4 days.
How were Pliant Therapeutics’s earnings last quarter?
Pliant Therapeutics released its earnings results on Feb 27, 2024. The company reported -€0.647 earnings per share for the quarter, beating the consensus estimate of -€0.764 by €0.116.
Is Pliant Therapeutics overvalued?
According to Wall Street analysts Pliant Therapeutics’s price is currently Undervalued.
Does Pliant Therapeutics pay dividends?
Pliant Therapeutics does not currently pay dividends.
What is Pliant Therapeutics’s EPS estimate?
Pliant Therapeutics’s EPS estimate is -€0.72.
How many shares outstanding does Pliant Therapeutics have?
Currently, no data Available
What happened to Pliant Therapeutics’s price movement after its last earnings report?
Pliant Therapeutics reported an EPS of -€0.647 in its last earnings report, beating expectations of -€0.764. Following the earnings report the stock price went down -3.145%.
Which hedge fund is a major shareholder of Pliant Therapeutics?
Among the largest hedge funds holding Pliant Therapeutics’s share is RA Capital Management. It holds Pliant Therapeutics’s shares valued at 23M.
---
Pliant Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€40.00 (257.13% Upside)
€40.00 (257.13% Upside)
Blogger Sentiment
Bullish
DE:9PT Sentiment 100%
Sector Average 70%
Sector Average 70%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-58.15%
12-Months-Change
Fundamentals
Return on Equity
-41.00%
Trailing 12-Months
Asset Growth
46.07%
Trailing 12-Months
Company Description
Pliant Therapeutics
Pliant Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Its lead product candidate, PLN-74809, is an oral small-molecule dual that helps in the treatment of idiopathic pulmonary fibrosis.
---
9PT Stock 12 Months Forecast
Average Price Target
€40.00
▲(257.13% Upside)
Technical Analysis
Pliant Therapeutics
―
Kura Oncology
―
Gritstone Oncology
―
Avrobio
―
Meiragtx Holdings
―
Best Analysts Covering 9PT
1 Year
1 Year Success Rate
6/17 ratings generated profit
1 Year Average Return
+45.71%
reiterated a buy rating 2 months ago
Copying Ed Arce's trades and holding each position for 1 Year would result in 35.29% of your transactions generating a profit, with an average return of +45.71% per trade.
---